ZIOPHARM Oncology (NASDAQ:ZIOP)

pchop123 (76.57) Submitted: 5/24/2013 11:11:09 AM : Start Price: $2.77 ZIOP Score: -5.82

momentum UP

zzlangerhans (99.78) Submitted: 4/30/2013 6:59:42 PM : Start Price: $1.70 ZIOP Score: +49.36

I'm a little behind on pitches by virtue of being limited to my smartphone for the last week while traveling. I managed to avoid the Ziopharm plunge in CAPS but lost a couple of thousand in real money on an ill-fated attempt at a bounce. Now I'm stepping back in a little more gingerly with 2500 shares bought at 1.63 for the Portefeuille collaboration on 4/19/13. I'm equivocal on the prospects here, but so far Portefeuille has maintained the track record that brought him amazing returns in his virtual fund. I'm dubious about the remaining trials of palifosfamide but with a strong cash position and enterprise value of 66M, the stock could have a run ahead of phase II data for Ad-RTS IL-12 in melanoma in the second half of the year.

RandomStockPicks (38.86) Submitted: 4/17/2013 12:15:24 AM : Start Price: $1.68 ZIOP Score: +50.24

Can a random number generator (www.random.org) produce the best 100 stock picks that will beat the market over the years? Let’s find out. :)

My process, for those interested:
I use www.random.org number generator to produce a number between 1 and 7,801. There are 7,801 stocks available to choose on the Motley Fool CAPS Game. Once I get a number, I go to the list, find that stock, and select that stock to outperform for the next five years.

Ezquire65 (46.98) Submitted: 5/22/2012 2:57:23 PM : Start Price: $4.74 ZIOP Score: -59.89

A true speculative play with huge upside potential. With master investory RJ Kirk behind this security and from all accounts many promising developments. This could be the proverbial 5 bagger holy grail that FOOLS rarely see.

mavrant (< 20) Submitted: 6/2/2011 12:36:29 PM : Start Price: $6.74 ZIOP Score: -87.03

possible new technology

AGCAPS1 (20.59) Submitted: 1/26/2011 10:19:00 AM : Start Price: $5.98 ZIOP Score: +83.52

First review the released statements since 2009. Then read about what this company does. They research on eliminations of the existent cancer drugs side effects. This company works in drugs researching provided by Intrexon. If they become successful “many years away”, most likely the Intrexon will be the one profit from it. The stock is overpriced.